- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06386315
Radioterapia de dosis reducida para el tratamiento del linfoma no Hodgkin indolente
Radioterapia hipofraccionada de dosis reducida (3 Gy x 3 fracciones) para el linfoma no Hodgkin indolente (POSEIDON): un ensayo aleatorizado de fase 2 en varios sitios
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
PRIMARY OBJECTIVE:
I. To show that the experimental arm [9 gray (Gy) in 3 fractions, 8 Gy in 2 fractions, or 10 Gy in 5 fractions] has significantly reduced acute toxicity (grade ≥ 2 adverse events at least possibly related to radiation treatment within 14 days after the end of radiation treatment [according to Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0] compared to 24 Gy in 12 fractions.
SECONDARY OBJECTIVES:
I. To evaluate patient reported quality of life. II. To evaluate response rate. III. To evaluate local control rate. IV. To evaluate relapse-free survival.
EXPLORATORY OBJECTIVES:
I. Financial toxicity will be assessed at the end of radiation treatment. II. Financial health care expenditure will be assessed at the end of radiation treatment III. Late toxicity.
CORRELATIVE RESEARCH OBJECTIVES:
I. Biopsies of enrolled patients will be evaluated for pathological assessment of cellular and genetic mutations to correlate them with disease local relapse and radiation resistance.
II. Patients will have their baseline positron emission tomography (PET)/computed tomography (CT) scan undergo auto-segmentation to calculate the functional imaging 18-fluoro-deoxyglucose (FDG) metabolic tumor volume (MTV), total lesions glycolysis (TLG) and maximum standardized uptake volume (SUVmax) of the sites to be treated with involved-site radiation therapy (ISRT) using MIMvista platform to correlate it with disease local relapse and treatment response.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo reduced dose ISRT once daily (QD) over 3, 2, or 5 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.
ARM II: Patients undergo standard of care (SOC) radiation therapy QD over 12 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up.
After completion of study treatment, patients are followed up at days 7 and 14, months 3 and 6, and then every 6 months for up to 2 years post-radiation therapy.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Clinical Trials Referral Office
- Número de teléfono: 855-776-0015
- Correo electrónico: mayocliniccancerstudies@mayo.edu
Ubicaciones de estudio
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85259
- Reclutamiento
- Mayo Clinic in Arizona
-
Contacto:
- Clinical Trials Referral Office
- Número de teléfono: 855-776-0015
- Correo electrónico: mayocliniccancerstudies@mayo.edu
-
Investigador principal:
- William G. Rule, MD
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224-9980
- Reclutamiento
- Mayo Clinic in Florida
-
Contacto:
- Clinical Trials Referral Office
- Número de teléfono: 855-776-0015
- Correo electrónico: mayocliniccancerstudies@mayo.edu
-
Investigador principal:
- Brad S. Hoppe, MD, MPH
-
-
Minnesota
-
Albert Lea, Minnesota, Estados Unidos, 56007
- Reclutamiento
- Mayo Clinic Health System in Albert Lea
-
Contacto:
- Clinical Trials Referral Office
- Número de teléfono: 855-776-0015
- Correo electrónico: mayocliniccancerstudies@mayo.edu
-
Investigador principal:
- John Yeakel, MD
-
Mankato, Minnesota, Estados Unidos, 56001
- Retirado
- Mayo Clinic Health System - Mankato
-
Rochester, Minnesota, Estados Unidos, 55905
- Reclutamiento
- Mayo Clinic in Rochester
-
Contacto:
- Clinical Trials Referral Office
- Número de teléfono: 855-776-0015
- Correo electrónico: mayocliniccancerstudies@mayo.edu
-
Investigador principal:
- Scott C. Lester, MD
-
-
Wisconsin
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Reclutamiento
- Mayo Clinic Health System-Eau Claire Clinic
-
Contacto:
- Clinical Trials Referral Office
- Número de teléfono: 855-776-0015
- Correo electrónico: mayocliniccancerstudies@mayo.edu
-
Investigador principal:
- Now Bahar Alam, MD
-
La Crosse, Wisconsin, Estados Unidos, 54601
- Reclutamiento
- Mayo Clinic Health System-Franciscan Healthcare
-
Contacto:
- Clinical Trials Referral Office
- Número de teléfono: 855-776-0015
- Correo electrónico: mayocliniccancerstudies@mayo.edu
-
Investigador principal:
- Abigail L. Stockham, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Age ≥ 18 years
-
Histological confirmation of indolent B-cell lymphoma that can include any of the following:
- Follicular lymphoma (grade 1 or 2 or 3A)
- Marginal zone lymphoma (nodal or extranodal)
- Follicle center lymphoma
-
Any stage disease
-
Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3
-
Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only
-
Provide written informed consent
-
Ability to complete questionnaire(s) by themselves or with assistance
-
Willing to return to enrolling institution for follow-up visits (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items
-
Confirmation from radiation oncologist of suitability to participate in study
Exclusion Criteria:
-
Any of the following:
- Pregnant women
- Nursing women
- Women of childbearing potential who are unwilling to employ adequate contraception
-
T-cell lymphoma
-
Receiving treatment for small and chronic lymphocytic lymphoma
-
Grade 3B follicular lymphoma
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: ARM 1 (reduced dose ISRT)
Patients undergo reduced dose ISRT once daily (excluding weekends): 9 Gy delivered in 3 treatment fractions or 8 Gy in 2 fractions. At physician discretion, patients may receive 10 Gy in 5 fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up. |
Ancillary studies Undergo CT or PET/CT
Otros nombres:
Undergo PET/CT
Otros nombres:
Undergo endoscopy
Otros nombres:
Undergo ISRT in 3 fractions
Otros nombres:
|
|
Comparador activo: ARM 2 (SOC ISRT)
Patients undergo standard of care (SOC) radiation therapy once daily (excluding weekends): 24 Gy in 12 treatment fractions. Patients also undergo CT or PET/CT throughout the study. Patients may additionally undergo endoscopy during screening and during follow up. |
Ancillary studies Undergo CT or PET/CT
Otros nombres:
Undergo PET/CT
Otros nombres:
Undergo endoscopy
Otros nombres:
Undergo ISRT in 12 fractions
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of grade 2 or higher acute adverse events (AEs)
Periodo de tiempo: Up to 14 days after radiation treatment
|
AEs will be graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Acute toxicity will be reported as a proportion calculated as the number of patients with acute toxicity divided by the total number of treatment patients. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2). |
Up to 14 days after radiation treatment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Response rate
Periodo de tiempo: Up to 3 months after radiation treatment
|
Response rate will be defined as the proportion of patients displaying response (complete response or partial response) at 3 months post treatment. Complete response is defined as the disappearance of all signs of cancer in response to treatment. Partial response is defined decrease in the size of target lesions by ≥ 50%, with no increase in the size of any lesion and no appearance of new lesions. Treated patients who do not have a 3-month evaluation will be classified as a non-response. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2). |
Up to 3 months after radiation treatment
|
|
Time to progression rate
Periodo de tiempo: Up to 24 months after radiation treatment
|
Local control will be defined as the number of days from end of radiation treatment until first local recurrence within 24 months post radiation treatment. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2). |
Up to 24 months after radiation treatment
|
|
Patient reported quality of life
Periodo de tiempo: Up to 3 months after radiation treatment
|
Patient reported quality of life will be measured using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale, a 13-item questionnaire answered on a scale of 1-5 where 1=Not at all and 5=Very much. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2). |
Up to 3 months after radiation treatment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Brad S. Hoppe, MD, MPH, Mayo Clinic
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Técnicas de investigación
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Procedimientos quirúrgicos, operativo
- Procedimientos quirúrgicos mínimamente invasivos
- Técnicas de diagnóstico, quirúrgico
- Técnicas de química, analítica
- Análisis de espectro
- Espectroscopía de resonancia magnética
- Endoscopia
Otros números de identificación del estudio
- MC230808
- 23-010273 (Otro identificador: Mayo Clinic Institutional Review Board)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .